TABLE 4.
Pharmacokinetics of rosuvastatin in individuals with different ABCG2 c.421C > A (ACBG2*2) genotypes
| Variable | ABCG2 c.421C/C (n = 206) | ABCG2 c.421C/A (n = 36) | ABCG2 c.421A/A (n = 5) | ||
|---|---|---|---|---|---|
| Mean (90% CI) | Mean (90% CI) | Ratio to c.421C/C (90% CI); P‐value | Mean (90% CI) | Ratio to c.421C/C (90% CI); P‐value | |
| C max (ng/mL) | 16.4 (14.4–18.6) | 16.8 (14.1–20.0) | 1.03 (0.83–1.27); P = .85 | 33.3 (22.8–48.6) | 2.04 (1.37–3.03); P = .0036 |
| AUC0‐∞ (ng × h/mL) | 138.7 (124.4–154.5) | 159.0 (137.0–184.5) | 1.15 (0.95–1.38); P = .22 | 298.6 (215.9–413.1) | 2.16 (1.53–3.03); P = 2.6 × 10 −4 |
| t ½ (h) | 11.5 (10.5–12.6) | 11.4 (10.1–12.9) | 0.99 (0.85–1.16); P = .94 | 10.6 (8.0–13.9) | 0.92 (0.69–1.23); P = .64 |
Data are estimated marginal means adjusted for weight (AUC0‐∞ and C max), SLCO2B1 c.1457C > T genotype and SLCO1B1 genotype‐predicted OATP1B1 function. AUC0–∞, area under the plasma concentration–time curve from zero to infinity; CI, confidence interval; C max, peak plasma concentration; t ½, elimination half‐life.